➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Merck

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Imexon

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Imexon?

Imexon is an investigational drug.

There have been 8 clinical trials for Imexon. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Burkitt Lymphoma, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are AmpliMed Corporation, University of Rochester, and University of Arizona.

Recent Clinical Trials for Imexon
TitleSponsorPhase
Imexon for Relapsed Follicular and Aggressive LymphomasUniversity of ArizonaPhase 2
Imexon for Relapsed Follicular and Aggressive LymphomasUniversity of RochesterPhase 2
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung CancerAmpliMed CorporationPhase 2

See all Imexon clinical trials

Clinical Trial Summary for Imexon

Top disease conditions for Imexon
Top clinical trial sponsors for Imexon

See all Imexon clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.